Regeneron Pharmaceuticals, Inc.
Formulations of VEG antagonist fusion proteins and method of manufacturing them

Abstract:

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.